Odyssey Therapeutics, Inc. Common Stock (ODTX) — Cash Flow-to-Debt Ratio
Odyssey Therapeutics, Inc. Common Stock (ODTX) has a Cash Flow-to-Debt Ratio of -0.55x as of June 2026, meaning its operating cash flow of $-34.51 Million could theoretically repay -1% of its total liabilities ($62.63 Million) in one year. See Odyssey Therapeutics, Inc. Common Stock (ODTX) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Odyssey Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Odyssey Therapeutics, Inc. Common Stock across 4 annual periods. See net asset quality index of Odyssey Therapeutics, Inc. Common Stock to measure how much of total assets are equity-financed.
Annual Cash Flow-to-Debt Ratio for Odyssey Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year debt coverage analysis for Odyssey Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see how efficiently does Odyssey Therapeutics, Inc. Common Stock generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.17x | $-129.47 Million | $758.07 Million | ▲ +15.7% |
| 2024 | -0.20x | $-117.47 Million | $579.96 Million | ▲ +1.3% |
| 2023 | -0.21x | $-112.73 Million | $549.23 Million | ▲ +5.1% |
| 2022 | -0.22x | $-99.84 Million | $461.77 Million | — |